Strategic Acquisition ImaginAb has been acquired by Telix Pharmaceuticals for $73M as of January 2025, signaling a strategic consolidation of radiopharmaceutical imaging assets. This presents an opportunity to engage Telix (and related portfolio companies) for ongoing licensing, co-development, or market expansion discussions leveraging ImaginAb's CD8 ImmunoPET imaging assets.

Lead Asset Focus Post-acquisition the company will concentrate on its lead imaging candidate, CD8 ImmunoPET, currently in Phase II and licensed for use in immunotherapy oncology trials. This creates a target opportunity to position imaging agents as companion diagnostics or as endpoints for immuno-oncology trials with pharma partners seeking validated imaging biomarkers.

Clinical Trials Network ImaginAb’s imaging platform has already been licensed by numerous pharmaceutical and biotech companies for use in immunotherapy trials, indicating a broad potential customer base including CROs and biopharma sponsors running oncology IO trials that could adopt or co-develop radiopharmaceutical imaging solutions.

Strategic Partnerships Recent collaborations and preclinical/license agreements (e.g., with Oncodesign Services) suggest ongoing openness to preclinical and translational partnerships. This presents a channel for BD outreach to establish new licensing, out-licensing, or research collaboration deals around imaging assets and radiopharmaceutical platforms.

Funding and Growth With a revenue range of $1–10M and total funding around $60M, ImaginAb shows financial momentum typical of growth-stage biotech sellers or partners. Identifying buyers or co-development partners seeking late-stage imaging assets or radiopharmaceutical therapies could unlock strategic collaborations or acquisition discussions aligned with their capital plans.